Patents by Inventor Dong-Ming Shen

Dong-Ming Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12084424
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: September 10, 2024
    Assignee: Novartis AG
    Inventors: Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler
  • Publication number: 20230416211
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 28, 2023
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Patent number: 11724992
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: August 15, 2023
    Assignee: Novartis AG
    Inventors: Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler
  • Patent number: 11718631
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: August 8, 2023
    Assignee: Novartis AG
    Inventors: Shankar Venkatraman, Shomir Ghosh, William R. Roush, Dong-Ming Shen, Jason Katz, Hans Martin Seidel
  • Publication number: 20230079631
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: May 11, 2022
    Publication date: March 16, 2023
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, JR., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Publication number: 20230063462
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: January 23, 2020
    Publication date: March 2, 2023
    Inventors: Jason KATZ, William R. ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN
  • Publication number: 20230062815
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: October 7, 2021
    Publication date: March 2, 2023
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, JR., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Publication number: 20230059136
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: November 14, 2019
    Publication date: February 23, 2023
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Publication number: 20230051589
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: November 14, 2019
    Publication date: February 16, 2023
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Publication number: 20230031406
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: November 11, 2019
    Publication date: February 2, 2023
    Inventors: Shomir GHOSH, Gary GLICK, Jason KATZ, William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN
  • Publication number: 20230024859
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: November 11, 2019
    Publication date: January 26, 2023
    Inventors: Jason KATZ, William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN
  • Publication number: 20230025630
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: November 11, 2019
    Publication date: January 26, 2023
    Inventors: Shomir GHOSH, Jason KATZ, William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN
  • Publication number: 20230011652
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: October 23, 2019
    Publication date: January 12, 2023
    Inventors: William ROUSH, Shankar VENKATRAMAN, Shomir GHOSH, Dong-Ming SHEN, Jason KATZ, Hans Martin SEIDEL
  • Publication number: 20220387397
    Abstract: In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 8, 2022
    Inventors: William ROUSH, Shankar VENKATRAMAN, Shomir GHOSH, Dong-Ming SHEN, Jason KATZ, Hans Martin SEIDEL
  • Publication number: 20220339169
    Abstract: Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and/or expression as compared to a reference level. Provided herein are methods of treating a subject, methods of selecting a treatment for a subject, methods of selecting a subject for treatment, and methods of selecting a subject for participation in a clinical study that include the administration of a therapeutically effective amount of an NLRP3 antagonist. Also provided are methods of treating a subject having resistance to an anti-TNF? agent and methods of determining the efficacy of treatment with an anti-TNF? agent. Also provided are methods of treating a subject with a combination of an NLRP3 antagonist and an anti-TNF? agent.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 27, 2022
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William R. ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Publication number: 20220340591
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein.
    Type: Application
    Filed: October 12, 2018
    Publication date: October 27, 2022
    Applicant: Novartis AG
    Inventors: Shankar VENKATRAMAN, Shomir GHOSH, William R. ROUSH, Dong-Ming SHEN, Jason KATZ, Hans Martin SEIDEL
  • Patent number: 11447460
    Abstract: In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 20, 2022
    Assignee: Novartis AG
    Inventors: Gary Glick, Shomir Ghosh, William R. Roush, Dong-Ming Shen
  • Publication number: 20220267276
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.
    Type: Application
    Filed: July 2, 2019
    Publication date: August 25, 2022
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William R. ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • Publication number: 20220227707
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula (AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 21, 2022
    Inventors: Jason KATZ, Dong-Ming SHEN
  • Patent number: 11370763
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 28, 2022
    Assignee: NOVARTIS AG
    Inventors: Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler